James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

10 Pharmaceutical Stocks to Buy for the Dividends

Surprise! This sliver of the healthcare sector not known for dishing out income serves up some decent dividend stocks.

5 Rare Bright Spots in a Troubled China

Don't assume the entire Chinese stock market is nothing but trouble. Here are some solid Chinese stocks regardless of what comes next.

Why AtriCure Inc. (ATRC), Valeant Pharmaceuticals Intl Inc (VRX) and FireEye Inc (FEYE) Are 3 of Today’s Worst Stocks

AtriCure (ATRC), Valeant Pharmaceuticals (VRX) and FireEye (FEYE) each used more than their fair share of red ink on Monday.

This Is the Best Thing to Happen to GE Stock in Years

GE stock has been a lackluster performer for years, but this activist's involvement may well convince the market of the company's true value.

Why Bank of America Corp (BAC), Interactive Brokers Group, Inc. (IBKR) and United Continental Holdings Inc. (UAL) Are 3 of Today’s Worst Stocks

Why Bank of America Corp. (BAC), Interactive Brokers Group, Inc. (IBKR) and United Continental Holdings Inc. (UAL) Are 3 of Today's Worst Stocks